Login to Your Account



Clinic Roundup


Wednesday, July 27, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., said the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio started a 28-patient trial of TH-302 in combination with Avastin (bevacizumab, Roche AG) in patients with recurrent high-grade astrocytoma, including glioblastoma. The study will enroll patients whose disease has progressed following both combined modality treatment with radiation and temozolomide chemotherapy, as well as therapy with Avastin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription